NHWA Pharmaceutical Gains Approval for New Drug Registration       

Jiangsu NHWA Pharmaceutical Co., Ltd. (SZ: 002262) said it on February 5th received the approval notice from China's State Food and Drug Administration (SFDA) to produce ziprasidone mesylate technical and injection.
   Xuzhou, Jiangsu province-based NHWA Pharmaceutical engages in the manufacture of central nervous system pharmaceutical formulations and medical raw materials.
   Ziprasidone mesylate for injection is a new drug for the treatment of acute agitation in schizophrenic patients in the Chinese market. The company became the first one in China to gain approval to produce this drug.
   The grant for production and sales of ziprasidone mesylate would boost the company's profitability, NHWA Pharmaceutical said.